Table 1.

Results of Simulated In-Use Testing over Inhaler Lifetime, After Storage in Secondary Packaging in Controlled (25°C and 60% Relative Humidity) or Ambient Laboratory Conditions

		FPM, mean (range) % nominal blister content
		Controlled conditions (25°C and 60% relative humidity)			Ambient laboratory conditions
Flow rate (L/min)	Product delivered	UMEC	FF	VI	UMEC	FF	VI
60	FF monotherapy (100 μg)a		23.7 (20.9–25.6)			–
	UMEC monotherapy (62.5 μg)	35.0 (31.3–38.8)			34.4 (30.3–36.7)
	FF/VI (100/25 μg)		20.6 (18.0–22.2)	30.7 (27.5–34.2)		18.5 (16.5–21.0)	31.0 (28.2–33.8)
	FF/VI (200/25 μg)		20.1 (18.1–21.2)	29.5 (25.8–32.8)		18.6 (16.9–20.4)	30.8 (28.9–32.9)
	UMEC/VI (62.5/25 μg)	31.5 (29.4–33.3)		28.4 (26.0–30.5)	31.8 (29.0–35.4)		27.0 (23.2–31.8)

Data are mean (range). ^aAssessments after storage under ambient conditions were not performed.

FF, fluticasone furoate; FPM, fine particle mass; UMEC, umeclidinium; VI, vilanterol.